Clinical trial
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
NCT00467025 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00467025 |
|---|---|
| Title | AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib |
| Official title | A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | AMG 386, Sorafenib, AMG 386 placebo IV |
| Enrollment | 152 |
| Start date | May 1, 2007 |
| Primary completion | Apr 1, 2010 |
| Completion | Jun 1, 2014 |
| First posted | Apr 27, 2007 |
| Last update posted | Mar 23, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: